nct_id: NCT04892173
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2021-05-19'
study_start_date: '2022-01-04'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: JNJ-90301900 (NBTXR3)'
  - drug_name: 'Drug: Cetuximab'
  - drug_name: 'Radiation: Radiation Therapy'
long_title: A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy
  Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible
  Elderly Patients With LA-HNSCC
last_updated: '2025-11-07'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Johnson & Johnson Enterprise Innovation Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 500
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Age greater than or equal to (\>=) 60 years old'
- '* Squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or supraglottic
  larynx and a candidate for definitive radiation therapy with or without cetuximab'
- '* Clinical stage T3-4 NX or T2 N2-3 disease according to the 8th edition of AJCC'
- '* One primary tumor lesion amendable for intratumoral injection'
- '* Ineligible to receive platinum-based chemotherapy with radiation (at least one
  of the following):'
- 1. Estimated creatinine clearance \>= 30 and less than (\<) 50 milliliters/minute
  (mL/min) (per Cockcroft-Gault equation), Grade \>= 2 hearing loss or tinnitus, Grade
  \>= 2 peripheral neuropathy, Eastern Cooperative Oncology Group (ECOG) Performance
  Status 2 or New York Heart Association Class 3
- 2. Age 70-74 years old with Geriatric 8 (G8) score less than or equal to (\<=) 14
- 3. Age \>= 75 years old
- 'Exclude - Exclusion Criteria:'
- Exclude - * Carcinoma of the nasopharynx, paranasal sinus(es), salivary gland, thyroid
  gland, or unknown primary
- Exclude - * Non-squamous cell histology
- Exclude - * Clinical stage T1-2 N0, T2 N1, or M1 disease according to the 8th edition
  of AJCC
- Exclude - * Loco-regionally recurrent head \& neck cancer that has been previously
  treated with surgery, radiation therapy, and/or chemotherapy
- Exclude - * Prior or concurrent primary malignancy (including second synchronous
  head \& neck cancer) within the last 2 years of informed consent and whose natural
  history has the potential to interfere with the safety and efficacy assessment of
  the investigational agent
- Exclude - * Ongoing or active infection requiring treatment with antimicrobial therapy
  within 2 weeks of randomization
short_title: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab
  in LA-HNSCC
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Johnson & Johnson Enterprise Innovation Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: "This is a global, open-label, randomized, 2-arm, Investigator's choice Phase\
  \ 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900\
  \ (NBTXR3) / radiation therapy (RT)\xB1cetuximab versus RT\xB1cetuximab in treatment-na\xEF\
  ve, platinum-ineligible, elderly participants with locally advanced head and neck\
  \ squamous cell carcinoma (LA-HNSCC)."
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Arm A
      arm_internal_id: 0
      arm_description: JNJ-90301900 (NBTXR3), as an intratumoral/intranodal injection,
        activated by investigator's choice of RT alone or RT in combination with cetuximab.
        JNJ-90301900 (NBTXR3) is given as a dose of 33% of the Gross Tumor Volume.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: JNJ-90301900 (NBTXR3)'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Cetuximab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Radiation: Radiation Therapy'
        level_internal_id: 2
        level_suspended: N
    - arm_code: Arm B
      arm_internal_id: 1
      arm_description: Investigator's choice of RT alone or RT in combination with
        cetuximab.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Cetuximab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Radiation: Radiation Therapy'
        level_internal_id: 1
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=60'
        disease_status:
        - Locally Advanced
        - Advanced
        - Recurrent
        oncotree_primary_diagnosis: Head and Neck Squamous Cell Carcinoma
